Osmol Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Osmol Therapeutics, Inc. - overview
Established
2016
Location
New Haven, CT, US
Primary Industry
Biotechnology
About
Founded in 2016 and based in Connecticut, US, Osmol Therapeutics, Inc. , dba Osmol, is a biopharmaceutical company that develops treatments to prevent chemotherapy-induced peripheral neuropathy related to taxane treatment. In April 2022, Osmol Therapeutics, Inc. raised USD 5.
2 million in Series A funding from Koax Investment Partners. As of 2022, Bob Linke is the CEO of the company. The company provides a drug candidate, OSM-0205, which is designed to prevent the off-target calcium surge caused by taxanes and potentially other chemotherapy treatments associated with peripheral nerve damage, resulting in a reduction in CIPN. The firm's product OSM-0205, a patent-protected drug administered intravenously immediately before chemotherapy, has the potential to protect neurons in patients by preventing the surge in intracellular calcium, thereby improving patient quality of life and optimizing chemotherapy.
The organization plans to use the April 2022 funding to support the development of OSM-0205 through an IND filing.
Current Investors
Koax Investment Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.osmoltherapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.